ADME & Predictive Toxicology Keynote Speakers

Robert Guttendorf Senior Consultant, DMPK, Aclairo Pharmaceutical Development Group Robert J. Guttendorf, R.Ph, Ph.D. is a Senior Consultant, DMPK, at Aclairo Pharmaceutical Development Group, Inc. in Vienna, VA. Dr. Guttendorf provides scientific, regulatory, strategic planning, and due diligence advice and support for drug discovery and development. He has held leadership positions in small biotech and large pharmaceutical companies, including Director of Discovery and Preclinical Development at Pfizer Global R&D and Parke-Davis Pharmaceutical Research, Scientific Strategy Advisor at Pfizer, Vice President of Pharmacology and Biopharmaceutics at Advancis (Middlebrook) Pharmaceutical Co., and Vice President of Pharmacology and Experimental Therapeutics at Sequoia Pharmaceuticals. He has directed ADME/PK support for discovery through NDA across a variety of therapeutic areas, overseeing numerous nonclinical pharm-tox and clinical pharmacology programs, and a host of regulatory submissions. At Parke-Davis/Pfizer, he helped pioneer the implementation of higher throughput ADME/PK screening approaches in drug discovery and was instrumental in defining best practices for DMPK in drug discovery and development. In addition, he led Pfizer’s Global PDM organization in evaluating and implementing new strategies to enhance the quality and R&D survival of exploratory development candidates. He has presented and published numerous papers on various topics in ADME/PK, including the strategic use of ADME data to improve drug discovery and development. He received a B.S. in Pharmacy from West Virginia University and a Ph.D. in Pharmaceutical Sciences from the University of Kentucky.
Thomas Joos Deputy Managing Director, University of Tuebingen Dr. Joos joined 1998 the NMI at the University of Tuebingen heading the department of biochemistry. Since 2013 he is the deputy managing director. His research is focused on miniaturized multiplexed immunoassays for biomarker research and diagnostic applications. Dr. Joos studied Biochemistry at the University of Tübingen. He performed his Ph.D. degree in 1985 on integrin-?5 during early embroygenesis of Xenopus laevis in the laboratory of Prof. Peter Hausen at the Max-Planck-Institute of Developmental Biology. Dr. Joos is a member of the editorial board of Drug Discovery Today, Proteomics, Molecular Biotechnology and Expert Review of Proteomics. He is a member of the scientific advisory board of the "Plasma Proteome Institute" Washington, DC, USA, of the “AlbaNova VINN Excellence Centre for Protein Technology (ProNova)” at the Royal Institute of Technology, Stockholm, Sweden, and of Myriad-RBM, Austin, TX, USA.
Hugo Kubinyi Retired Professor, BASF SE & University of Heidelberg Hugo Kubinyi studied chemistry in Vienna, Austria. After his Ph.D. thesis at the Max Planck Institute of Biochemistry in Munich he continued as a PostDoc at the German Cancer Research Centre in Heidelberg. In 1966 he joined Knoll AG, later a subsidiary of BASF AG. Development of a partial synthetic cardiac glycoside (Meproscillarin, CLIFT; launched 1978). In 1985 he moved to BASF AG. Since 1987, until his retirement in summer 2001, he was responsible for the Molecular Modelling, X-ray Crystallography and Drug Design group of BASF, since early 1998 also for Combinatorial Chemistry in the Life Sciences. In 1986 he was appointed as associate Professor of Pharmaceutical Chemistry at the University of Heidelberg. He is former Chair of the Cheminformatics and QSAR Society (1995-2000; from 2000-2007 Advisor to the Chair) and IUPAC Fellow. In 2006 he received the Herman Skolnik Award (CINF, ACS) and in 2008 the Nauta Award in Pharmacochemistry (EFMC) and the Nauta Chair (Vrije Universiteit, Amsterdam). From his scientific work resulted more than 100 publications and seven books on QSAR, 3D QSAR, Drug Design Design (the German book "Wirkstoffdesign" received the 1999 Book Award of the FCI, Association of Chemical Industry), Chemogenomics in Drug Discovery, and Drug Discovery Technologies (Volume 3 of Comprehensive Medicinal Chemistry II, 2006). He is a member of several Scientific Advisory Boards, coeditor of the Wiley-VCH book series "Methods and Principles in Medicinal Chemistry", and member of the Editorial Boards of several scientific journals.